B+
Bull case
25%
Probability
Target price
$25.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
SLS
SELLAS Life Sciences GroupDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$10.50
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-13
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+51.7
Score
AI commentary
The primary Q2 release confirms the company-source operating context: cash was $138.3 million, quarterly EPS was a loss of $0.05, R&D expense increased to $6.3 million, REGAL remained pending, and SLS009 enrollment reached 28 patients [#SEC-8K-2026-08-11]. Secondary packet headlines describe a roughly flat after-hours reaction followed by a stronger subsequent session, but they do not establish whether the move reflected earnings, clinical expectations, or broader trading. No verified post-print analyst revision was identified, so the later follow-up remains tentative and monitoring-oriented.
RankAlpha Sentiment Codex - 2026-08-13
Open post-earnings memoEvidence flagged
later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence
Impact
tentative
Confidence
-
AI events
2026-11-11eventREGAL Phase 3 reaches the 80th-event trigger and proceeds to topline analysisHigh impact
SELLAS said the pivotal REGAL AML trial will undergo database lock, blinded review, statistical analysis, unblinding, and topline disclosure after the pre-specified 80th event. The company did not disclose a current event count or timing in the Q2 update [#SEC-8K-2026-08-11].
2026-11-11catalystREGAL timing and efficacy remain unresolved after the earnings updateHigh impact
The Q2 company release reported no REGAL efficacy result and stated that final analysis remains dependent on reaching the 80th event. Delay, disappointing efficacy, or safety interpretation could therefore cause a material downside reaction [#SEC-8K-2026-08-11].
2027-08-13catalystSLS009 first-line AML Phase 2 enrollment and Q4 2026 topline dataHigh impact
The company reported 28 patients enrolled in the ongoing 80-patient Phase 2 study of SLS009 in newly diagnosed first-line AML, with topline data expected in Q4 2026 [#SEC-8K-2026-08-11].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-13 • Updated nightlySource: Internal modelMethodology